Form 4: Voyager Therapeutics Director Michael Higgins Granted 24,000 Stock Options Under 2025 Incentive Plan

Voyager Therapeutics, Inc. Director Michael J. Higgins was granted 24,000 stock options with an exercise price of $3.28 per share, vesting based on continued service.

Summary

• Michael J. Higgins, a Director of Voyager Therapeutics, Inc. (VYGR), acquired 24,000 stock options on June 3, 2025.
• Each option has an exercise price of $3.28 and is exercisable immediately upon grant.
• The options expire on June 3, 2035.
• These options were issued pursuant to the company's 2025 Stock Incentive Plan, aligning with its director compensation policy.
• The 24,000 shares of common stock underlying the options will vest upon the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, contingent on Mr. Higgins' continued service as a director.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a standard compensation practice that aligns director interests with shareholders, but it doesn't convey significant new operational or financial news.

Positives

• The granting of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance and commitment.
• The options are part of a structured 2025 Stock Incentive Plan, indicating a formal and transparent compensation strategy for directors.

Risks

• The vesting of the stock options is contingent upon Michael J. Higgins' continued service as a director, meaning the benefit is not guaranteed if his service ceases.
• The ultimate value of the stock options is dependent on Voyager Therapeutics, Inc.'s common stock price exceeding the exercise price of $3.28 in the future.

Future Outlook

The vesting schedule for the granted stock options indicates a future commitment from the director, with full vesting expected within one year or by the next annual meeting, subject to continued service.

Management Comments

• The stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy.

Industry Context

This transaction is a routine compensation event for a director in the biotechnology or pharmaceutical industry, where equity grants like stock options are common practice to align executive and director interests with shareholder value creation. Such grants are standard components of compensation packages designed to attract and retain talent in a highly competitive sector.

Comparison to Industry Standards

• The granting of stock options to directors is a common practice across the biotechnology and pharmaceutical industries, aligning with typical corporate governance and compensation strategies.
• While specific comparable companies or projects are not detailed in this Form 4, the use of a stock incentive plan and performance-based vesting (continued service) is consistent with compensation structures observed at peer companies like Biogen Inc. (BIIB) or Sarepta Therapeutics, Inc. (SRPT), which also utilize equity awards to incentivize long-term commitment and performance from their board members.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution upon exercise of options, but also potential benefit from aligned director incentives and long-term commitment.

Next Steps

• Continued service of Michael J. Higgins as a director for the options to vest.
• Future exercise of the options by Michael J. Higgins, subject to vesting and market conditions.
• The next annual meeting of stockholders, which is a potential vesting trigger for the options.

Key Dates

Recommendation

Keywords

Voyager Therapeutics, VYGR, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Michael J. Higgins, SEC Filing